UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. and LUPIN PHARMACEUTICALS INC. Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and BAUSCH & LOMB PHARMA HOLDINGS CORP. Patent Owner

> IPR2015-01097 (US Patent No. 8,754,131) IPR2015-01099 (US Patent No. 8,669,290) IPR2015-01100 (US Patent No. 8,927,606) IPR2015-01105 (US Patent No. 8,871,813)<sup>1</sup>

## **PETITIONERS' MOTION TO SEAL**

<sup>&</sup>lt;sup>1</sup> The word-for-word identical paper is filed in each proceeding identified in the heading. IPR2016-00089 has been joined with IPR2015-01097; IPR2016-00091 has been joined with IPR2015-01100; and IPR2016-00090 has been joined with IPR2015-01105. Each of these joined proceedings includes Petitioners InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (collectively, "InnoPharma") in addition to the parties identified above.

Pursuant to 37 C.F.R. §§ 42.14 and 42.55 and the Protective Orders entered in these proceedings, Petitioners hereby move to seal Exhibit 1181, the Deposition Transcript of Ivan T. Hofmann in IPR2015-00902 and IPR2015-00903, March 25, 2016. It is Petitioners' understanding that this document has been designated by Patent Owner as Protective Order Material or Fed. R. Evid. 615 Materials (*see* Paper 29 in IPR2015-01097; Paper 25 in IPR2015-01099; Paper 29 in IPR2015-01100; and Paper 29 in IPR2015-01105) ("Proposed Stipulated Protective Orders").

The record of an *inter partes* review proceeding, including documents and things, is made available to the public, except as otherwise ordered. 37 C.F.R. § 42.14. Despite the default rule of public availability, the Board will seal confidential information for "good cause," because it is necessary to "strike a balance between the public's interest in maintaining a complete and understandable file history and the parties' interest in protecting truly sensitive information." 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).

Petitioners have no independent basis for this document to be sealed and thus make no assertion as to whether or not it may contain confidential information. Respectfully submitted,

May 18, 2016

/Deborah Yellin/

Deborah H. Yellin Reg. No. 45,904 CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300

## **CERTIFICATION OF SERVICE**

The undersigned hereby certifies that the foregoing document entitled PETITIONERS' MOTION TO SEAL was served electronically via email on May 18, 2016 to Patent Owner's counsel of record and counsel of record for Petitioners InnoPharma at the following:

## Patent Owner

Bryan.Diner@finnegan.com

Justin.Hasford@finnegan.com

Joshua.Goldberg@finnegan.com

## Petitioners InnoPharma

Jitty.malik@alston.com

bryan.skelton@alston.com

James.abe@alston.com

Lance.soderstrom@alston.com

Joe.janusz@alston.com

Respectfully submitted,

May 18, 2016

/Shannon M. Lentz/ Shannon M. Lentz Reg. No. 65,382 CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300